Heparin-coated bypass circuits (Carmeda) suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 12, Issue 3, 1998, Pages 299-304

  Spiess, B D ^a   Vocelka, C ^a   Cochran, R P ^a   Soltow, L ^a   Chandler, W L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cardiopulmonary bypass; Coagulation; Coronary artery bypass graft surgery; Fibrinolysis; Heparin coated circuit; Tissue plasminogen activator

Indexed keywords

ANTITHROMBIN III; HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTAMINE; PROTHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOLYSIS; HEMATOCRIT; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT;

EID: 0031865285     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-0770(98)90010-6     Document Type: Article

References (42)

1. S Khuri J Wolfe M Josa Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss J Thorac Cardiovasc Surg 104 1992 94 107
2. R Bick Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits Semin Thromb Hemost 11 1985 249 280
3. CS Rinder J Mathew HM Rinder Modulation of platelet surface adhesion receptors during cardiopulmonary bypass Anesthesiology 75 1991 563 568
4. AW Bracey R Radovancevic The hematologic effects of cardiopulmonary bypass and the use of hemotherapy in coronary artery bypass grafting Arch Pathol Lab Med 118 1994 411 416
5. G Valen E Erikson B Risberg J Vaage Fibrinolysis during cardiac surgery: Release of tissue plasminogen activator in arterial and coronary sinus blood Eur J Cardio Thorac Surg 8 1994 324 330
6. WL Chandler JCK Fitch MH Wall Individual variations in the fibrinolytic response during and after cardiopulmonary bypass Thromb Haemost 74 1995 1293 1297
7. J Paramo J Rifon R Llorens Intra- and postoperative fibrinolysis in patients undergoing cardiopulmonary bypass surgery Haemostasis 21 1991 58 64
8. K Tanaka M Takao I Yaka Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery J Cardiothorac Anesth 3 1989 181 188
9. I Gouin T Lecompte MC Morel In vitro effect of plasmin on human platelet function in plasma Inhibition of aggregation caused by fibrinogenolysis ed 9 Circulation 85 1992 935 941
10. S Niewiarowski A Senyi P Gillies Plasmin-induced platelet aggregation and platelet release reaction: Effects on hemostasis J Clin Invest 52 1973 1647 1659
11. B Pasche H Ouimet S Francis J Loscalzo Structural changes in platelet glycoprotein IIb/IIIa by plasmin: Determinants and functional consequences Blood 83 1994 404 414
12. G Fuhrer MJ Gallimore W Heller H Hoffmeister Studies on components of the plasma kallikrein-kinin system in patients undergoing cardiopulmonary bypass Adv Exp Med Biol 198B 1986 385 391
13. YT Wachtfogel PC Harpel LH Edmunds RH Colman Formation of Cl-Cl-inhibitor, kallikrein-C1-inhibitor, and plasmin-a2-antiplasmin-inhibitor complexes during cardiopulmonary bypass surgery Blood 73 1989 468 471
14. KM High MT Snider G Bashein Principles of oxygenator function: Gas exchange, heat transfer, and blood-artificial surface interaction G Gravlee RF Davis JR Utley Cardiopulmonary Bypass Principles and Practice 1993 Williams & Wilkins Baltimore, MD 28 54
15. O Larm R Larsson P Olsson A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue Biomater Med Devices Artif Organs 11 1983 161 173
16. Y Ito Antithrombogenic heparin-bound polyurethanes J Biomater Appl 2 1987 235 265
17. L Bagge S Thelin J Hultman Heparin-coated CPB-sets increase biocompatibility and reduce endothelial cell damage in pigs J Cardiothorac Anesth 3 1989 84 90
18. J Borowiec S Thelin L Bagge Heparin-coated cardiopulmonary bypass circuits and 25% reduction of heparin dose in coronary artery surgery—A clinical study Ups J Med Sci 97 1992 55 66
19. L von Segesser M Lachat B Leskosek Cardiopulmonary bypass with low systemic heparinization: An experimental study Perfusion 5 1990 267 276
20. L von Segesser B Weiss E Garcia Reduced blood loss and transfusion requirements with low systemic heparinization: Preliminary clinical results in coronary revascularization Eur J Cardiothorac Surg 4 1990 639 643
21. J Borowiec S Thelin L Bagge Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass—A clinical study J Thorac Cardiovasc Surg 104 1992 642 647
22. J Borowiec A Bylock J van der Linden S Thelin Heparincoating reduces blood cell adhesion to arterial filters during coronary bypass: A clinical study Ann Thorac Surg 55 1993 1540 1545
23. L von Segesser B Weiss E Garcia M Turina Clinical application of heparin-coated perfusion equipment with special emphasis on patients refusing homologous transfusions Perfusion 6 1991 227 233
24. BD Spiess Coagulation dysfunction after cardiopulmonary bypass JP Williams Postoperative Management of the Cardiac Surgical Patient 1996 Churchill Livingstone New York, NY 175 199
25. M Ranby B Sundell TK Nilsson Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal TPA activity Thromb Haemost 62 1989 917 922
26. WL Chandler G Schmer JR Stratton Optimum conditions for the stabilization and measurement of tissue plasminogen activator activity in human plasma J Lab Clin Med 113 1989 362 371
27. P Holvoet H Cleemput D Collen Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA Thromb Haemost 54 1985 684 687
28. J Amiral V Plassart M Grosley Measurement of tPAPAI-1 complexes by ELISA, using monoclonal antibodies: Clinical relevance Thromb Res 8 1988 99 113 (suppl)
29. PJ Declerck M Verstreken D Collen An immunofunctional assay for active plasminogen activator inhibitor-1 (PAI-1) Fibrinolysis 2 1988 17 18
30. MC Alessi I Juhan-Vague PJ Declerck Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels Thromb Res 60 1990 509 516
31. JB Castillo AM Farag EF Mammen RJ Sachs Prothrombin times and clotable fibrinogen determinations on an automated coagulation laboratory (ACL-810) Thromb Res 55 1989 213 219
32. H Pelzer A Schwarz W Stuber Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against a synthetic peptide Thromb Haemost 65 1991 153 159
33. J Gram J Jespersen Improved assay of antithrombin-III. Effects of certain additives on thrombin and chromogenic peptide substrates Clin Chem 31 1985 1683 1688
34. RC Gorman NP Ziats AK Rao Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass J Thorac Cardiovasc Surg 111 1996 1 12
35. W VanOeveren MP Harder KJ Roozendaal Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass Ann Thorac Surg 6 1992 76 81
36. MD Boisclair DA Lane H Philippou Mechanisms of thrombin generation during surgery and cardiopulmonary bypass Blood 82 1993 3350 3357
37. H Nagaoka T Yamada R Hatano Clinical significance of bradykinin liberation during cardiopulmonary bypass and its prevention by a kallikrein inhibitor Jpn J Surg 5 1975 222 233
38. E Ovrum F Brosstad EA Holen Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass Circulation 92 1995 2579 2584
39. E Ovrum EA Holen G Tangen Completely heparinized cardiopulmonary bypass and reduced systemic heparin: Clinical and hemostatic effects Ann Thorac Surg 60 1995 365 371
40. RD Rosenberg Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism Am J Med 87 1989 2 9
41. K Hashimoto M Yamagishi T Sasaki Heparin and antithrombin III levels during cardiopulmonary bypass: Correlation with subclinical plasma coagulation Ann Thorac Surg 58 1994 799 805
42. HB Soloway TW Christiansen Heparin anticoagulation during cardiopulmonary bypass in an antithrombin-III deficient patient Am J Clin Path 73 1980 723 725